Literature DB >> 32016085

BRAF mutant metastatic colorectal cancers: new arrows in our quiver.

Chiara Cremolini1,2, Roberto Moretto1,2, Gemma Zucchelli1,2, Alfredo Falcone1,2.   

Abstract

Entities:  

Year:  2019        PMID： 32016085      PMCID： PMC6976512          DOI： 10.21037/atm.2019.08.118

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  20 in total

1.  PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.

Authors:  Lee S Schwartzberg; Fernando Rivera; Meinolf Karthaus; Gianpiero Fasola; Jean-Luc Canon; J Randolph Hecht; Hua Yu; Kelly S Oliner; William Y Go
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

2.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Authors:  Josep Tabernero; Takayuki Yoshino; Allen Lee Cohn; Radka Obermannova; Gyorgy Bodoky; Rocio Garcia-Carbonero; Tudor-Eliade Ciuleanu; David C Portnoy; Eric Van Cutsem; Axel Grothey; Jana Prausová; Pilar Garcia-Alfonso; Kentaro Yamazaki; Philip R Clingan; Sara Lonardi; Tae Won Kim; Lorinda Simms; Shao-Chun Chang; Federico Nasroulah
Journal:  Lancet Oncol       Date:  2015-04-12       Impact factor: 41.316

3.  Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.

Authors:  Van Morris; Michael J Overman; Zhi-Qin Jiang; Christopher Garrett; Shweta Agarwal; Cathy Eng; Bryan Kee; David Fogelman; Arvind Dasari; Robert Wolff; Dipen Maru; Scott Kopetz
Journal:  Clin Colorectal Cancer       Date:  2014-06-23       Impact factor: 4.481

4.  Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Authors:  Ryan B Corcoran; Thierry André; Chloe E Atreya; Jan H M Schellens; Takayuki Yoshino; Johanna C Bendell; Antoine Hollebecque; Autumn J McRee; Salvatore Siena; Gary Middleton; Kei Muro; Michael S Gordon; Josep Tabernero; Rona Yaeger; Peter J O'Dwyer; Yves Humblet; Filip De Vos; A Scott Jung; Jan C Brase; Savina Jaeger; Severine Bettinger; Bijoyesh Mookerjee; Fatima Rangwala; Eric Van Cutsem
Journal:  Cancer Discov       Date:  2018-02-05       Impact factor: 39.397

5.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Authors:  Michael J Overman; Sara Lonardi; Ka Yeung Mark Wong; Heinz-Josef Lenz; Fabio Gelsomino; Massimo Aglietta; Michael A Morse; Eric Van Cutsem; Ray McDermott; Andrew Hill; Michael B Sawyer; Alain Hendlisz; Bart Neyns; Magali Svrcek; Rebecca A Moss; Jean-Marie Ledeine; Z Alexander Cao; Shital Kamble; Scott Kopetz; Thierry André
Journal:  J Clin Oncol       Date:  2018-01-20       Impact factor: 44.544

6.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Authors:  Volker Heinemann; Ludwig Fischer von Weikersthal; Thomas Decker; Alexander Kiani; Ursula Vehling-Kaiser; Salah-Eddin Al-Batran; Tobias Heintges; Christian Lerchenmüller; Christoph Kahl; Gernot Seipelt; Frank Kullmann; Martina Stauch; Werner Scheithauer; Jörg Hielscher; Michael Scholz; Sebastian Müller; Hartmut Link; Norbert Niederle; Andreas Rost; Heinz-Gert Höffkes; Markus Moehler; Reinhard U Lindig; Dominik P Modest; Lisa Rossius; Thomas Kirchner; Andreas Jung; Sebastian Stintzing
Journal:  Lancet Oncol       Date:  2014-07-31       Impact factor: 41.316

7.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Authors:  Eric Van Cutsem; Josep Tabernero; Radek Lakomy; Hans Prenen; Jana Prausová; Teresa Macarulla; Paul Ruff; Guy A van Hazel; Vladimir Moiseyenko; David Ferry; Joe McKendrick; Jonathan Polikoff; Alexia Tellier; Rémi Castan; Carmen Allegra
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544

8.  Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.

Authors:  Sabine Venderbosch; Iris D Nagtegaal; Tim S Maughan; Christopher G Smith; Jeremy P Cheadle; David Fisher; Richard Kaplan; Philip Quirke; Matthew T Seymour; Susan D Richman; Gerrit A Meijer; Bauke Ylstra; Danielle A M Heideman; Anton F J de Haan; Cornelis J A Punt; Miriam Koopman
Journal:  Clin Cancer Res       Date:  2014-08-19       Impact factor: 12.531

Review 9.  The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.

Authors:  Gholamreza Safaee Ardekani; Seyed Mehdi Jafarnejad; Larry Tan; Ardavan Saeedi; Gang Li
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

10.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

Authors:  Scott Kopetz; Jayesh Desai; Emily Chan; Joel Randolph Hecht; Peter J O'Dwyer; Dipen Maru; Van Morris; Filip Janku; Arvind Dasari; Woonbook Chung; Jean-Pierre J Issa; Peter Gibbs; Brian James; Garth Powis; Keith B Nolop; Suman Bhattacharya; Leonard Saltz
Journal:  J Clin Oncol       Date:  2015-10-12       Impact factor: 44.544
View more
  1 in total

1.  Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis.

Authors:  Qiaoli Yi; Jinwu Peng; Zhijie Xu; Qiuju Liang; Yuan Cai; Bi Peng; Qingchun He; Yuanliang Yan
Journal:  Front Bioeng Biotechnol       Date:  2022-07-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.